MELCHARDT THOMAS
Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center
Publications
128 Publications
2023
Journal Articles
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group
Jansko-Gadermeir, B; Leisch, M; Gassner, FJ; Zaborsky, N; Dillinger, T; Hutter, S; Risch, A; Melchardt, T; Egle, A; Drost, M; Larcher-Senn, J; Greil, R; Pleyer, L
CANCERS. 2023; 15(8): 2305
Full papers/articles (Journal)
How I treat diffuse large B-cell lymphoma.
Melchardt, T; Egle, A; Greil, R;
ESMO Open. 2023; 8(1):100750
Reviews
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Schreder, M; Melchardt, T; Stute, N; Föhrenbach Quiroz, KT; Leisch, M; Egle, A; Scagnetti, L; Wolf, D; Beswick, R; Drost, M; Larcher-Senn, J; Grochtdreis, T; Vaisband, M; Hasenauer, J; Zaborsky, N; Greil, R; Stauder, R;
Cancers (Basel). 2023; 15(5):
Full papers/articles (Journal)
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
Wagner, SM; Magnes, T; Melchardt, T; Kiem, D; Weiss, L; Neureiter, D; Wagner, C; Aretin, MB; Nemec, S; Gamerith, G; Pall, G; Greil, R; Fuereder, T;
Anticancer Res. 2023; 43(3):1273-1282
Full papers/articles (Journal)
2022
Journal Articles
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.
Huemer, F; Hecht, S; Scharinger, B; Schlintl, V; Rinnerthaler, G; Schlick, K; Heregger, R; Melchardt, T; Wimmer, A; Mühlbacher, I; Koch, OO; Neureiter, D; Klieser, E; Seyedinia, S; Beheshti, M; Greil, R; Weiss, L;
J Cancer Res Clin Oncol. 2022;
Full papers/articles (Journal)
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group
Leisch, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, B; Petzer, A; Schreder, M; Kiesl, D; Vallet, S; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Drost, M; Greil, R; Pleyer, L
CANCERS. 2022; 14(10): 2459
Full papers/articles (Journal)
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Wöll, E; Greil, R; Weiss, L;
BMC Cancer. 2022; 22(1): 51
Full papers/articles (Journal)
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
Starzer, AM; Heller, G; Tomasich, E; Melchardt, T; Feldmann, K; Hatziioannou, T; Traint, S; Minichsdorfer, C; Schwarz-Nemec, U; Nackenhorst, M; Mullauer, L; Preusser, M; Berghoff, AS; Fuereder, T
J IMMUNOTHER CANCER. 2022; 10(3): e003420
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant NonEligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Ludwig, H; Melchardt, T; Sormann, S; Zojer, N; Andel, J; Hartmann, BL; Tinchon, C; Gunsilius, E; Podar, K; Egle, A; Willenbacher, W; Woll, E; Schreder, M; Ruckser, R; Bozic, B; Krauth, MT; Petzer, A; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Fillitz, M; Wang, SY; Knop, S; Kainz, S; Paiva, B; Greil, R
BLOOD. 2022; 140: 10185-10188.
Abstracts (Journal)
Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
Pleyer, L; Vaisband, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, BL; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Scagnetti, L; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Greil, R
BLOOD. 2022; 140: 1346-1349.
Abstracts (Journal)
2021
Journal Articles
Austrian recommendations for the management of essential thrombocythemia.
Buxhofer-Ausch, V; Heibl, S; Sliwa, T; Beham-Schmid, C; Wolf, D; Geissler, K; Krauth, MT; Krippl, P; Petzer, A; Wolfler, A; Melchardt, T; Gisslinger, H
Wien Klin Wochenschr. 2021; 133(1-2):52-61
Full papers/articles (Journal)
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.
Hatzl, S; Posch, F; Rezai, A; Gornicec, M; Beham-Schmid, C; Magnes, T; Wagner, S; Deutsch, A; Greinix, H; Uhl, B; Prochazka, KT; Egle, A; Greil, R; Melchardt, T; Linkesch, W; Schulz, E; Neumeister, P;
Support Care Cancer. 2021; 29(9): 519-5207.
Full papers/articles (Journal)
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature.
Heregger, R; Huemer, F; Hutarew, G; Hecht, S; Cheveresan, L; Kotzot, D; Schamschula, E; Rinnerthaler, G; Melchardt, T; Weiss, L; Greil, R;
ESMO Open. 2021; 6(4):100233
Reviews
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil, F; Hartl, M; Altorjai, G; Berghold, A; Riedl, R; Pecherstorfer, M; Mayrbäurl, B; De Vries, A; Schuster, J; Hackl, J; Füreder, T; Melchardt, T; Burian, M; Greil, R;
Eur J Cancer. 2021; 151: -210.
Full papers/articles (Journal)
Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy.
Kiem, D; Leisch, M; Neureiter, D; Haslauer, T; Egle, A; Melchardt, T; Topp, MS; Greil, R;
Int J Mol Sci. 2021; 22(11):
Case Reports
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Kiem, D; Wagner, S; Magnes, T; Egle, A; Greil, R; Melchardt, T;
INT J MOL SCI. 2021; 22(17):
Reviews
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.
Magnes, T; Wagner, S; Kiem, D; Weiss, L; Rinnerthaler, G; Greil, R; Melchardt, T;
Int J Mol Sci. 2021; 22(9):
Reviews
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Schlick, K; Zaborsky, N; Steiner, M; Greil, R; Egle, A; Melchardt, T;
Cancers (Basel). 2021; 13(4):
Full papers/articles (Journal)
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Zaborsky, N; Steiner, M; Weis, S; Greil, R; Egle, A; Melchardt, T;
ESMO Open. 2021; 6(1): 100012
Full papers/articles (Journal)
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Magnes, T; Wagner, SM; Melchardt, T; Weiss, L; Rinnerthaler, G; Huemer, F; Kopp, M; Gampenrieder, SP; Mayrbäurl, B; Füreder, T; Lenger, D; Andel, J; Egle, A; Greil, R;
Wien Klin Wochenschr. 2021; 133(21-22):-1136.
Full papers/articles (Journal)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer, L; Leisch, M; Kourakli, A; Padron, E; Maciejewski, JP; Xicoy Cirici, B; Kaivers, J; Ungerstedt, J; Heibl, S; Patiou, P; Hunter, AM; Mora, E; Geissler, K; Dimou, M; Jimenez Lorenzo, MJ; Melchardt, T; Egle, A; Viniou, AN; Patel, BJ; Arnan, M; Valent, P; Roubakis, C; Bernal Del Castillo, T; Galanopoulos, A; Calabuig Muñoz, M; Bonadies, N; Medina de Almeida, A; Cermak, J; Jerez, A; Montoro, MJ; Cortés, A; Avendaño Pita, A; Lopez Andrade, B; Hellstroem-Lindberg, E; Germing, U; Sekeres, MA; List, AF; Symeonidis, A; Sanz, GF; Larcher-Senn, J; Greil, R;
Lancet Haematol. 2021; 8(2): e135-e148.
Full papers/articles (Journal)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Hubalek, M; Petru, E; Sandholzer, M; Andel, J; Balic, M; Melchardt, T; Hauser-Kronberger, C; Schmitt, CA; Ulmer, H; Greil, R;
Ther Adv Med Oncol. 2021; 13: 17588359211042301
Full papers/articles (Journal)
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
Schlick, K; Hohla, F; Hamacher, F; Hackl, H; Hufnagl, C; Markus, S; Magnes, T; Gampenrieder, SP; Melchardt, T; Stattner, S; Hauser-Kronberger, C; Greil, R; Rinnerthaler, G
FUTUR SCI OA. 2021; 7(2): FSO644
Full papers/articles (Journal)
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.
Schlick, K; Markus, S; Huemer, F; Ratzinger, L; Zaborsky, N; Clemens, H; Neureiter, D; Neumayer, B; Beate, AS; Florian, S; Martin, V; Grundbichler, M; Weiss, L; Melchardt, T; Greil, R; Egle, A;
Pancreatology. 2021; 21(8):1466-1471
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
Manrique, I; Greil, R; Andel, J; Sormann, S; Hartmann, BL; Podar, K; Egle, A; Petzer, A; Zojer, N; Gunsilius, E; Ruckser, R; Bozic, B; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Schreder, M; Wang, SY; Willenbacher, W; Krauth, MT; Tinchon, C; Fillitz, M; Melchardt, T; Knop, S; Paiva, B; Ludwig, H
BLOOD. 2021; 138:
Abstracts (Journal)
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R
BLOOD. 2021; 138:
Abstracts (Journal)
2020
Journal Articles
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl, S; Buxhofer-Ausch, V; Schmidt, S; Webersinke, G; Lion, T; Piringer, G; Kuehr, T; Wolf, D; Melchardt, T; Greil, R; Thaler, J
HEMATOL ONCOL. 2020; 38(5): 792-798.
Full papers/articles (Journal)
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer, F; Leisch, M; Geisberger, R; Melchardt, T; Rinnerthaler, G; Zaborsky, N; Greil, R;
Int J Mol Sci. 2020; 21(8):
Reviews
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Asslaber, D; Roland, G; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A;
Oncol Lett. 2020; 19(2):-1558.
Full papers/articles (Journal)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rumpold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N
Leuk Lymphoma. 2020; 61(2):377-386
Full papers/articles (Journal)
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2020; 20(2):350
Corrections
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R;
J Clin Med. 2020; 9(6):
Full papers/articles (Journal)
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C;
Eur J Haematol. 2020; 104(3):251-258
Full papers/articles (Journal)
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner, SM; Melchardt, T; Greil, R;
DRUG TODAY. 2020; 56(3): 195-202.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Real-world data for immune checkpoint inhibitor therapy as first line treatment of recurrent or metastatic squamous cell cancer of the head and neck
Wagner, SM; Magnes, T; Minichsdorfer, C; Gamerith, G; Pall, G; Greil, R; Melchardt, T; Fureder, T
ONCOL RES TREAT. 2020; 43(SUPPL 4): 132-133.
Abstracts (Journal)
2019
Journal Articles
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R;
Cancer Med. 2019; 8(4):-1405.
Full papers/articles (Journal)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A;
Eur J Haematol. 2019; 102(5): 437-441.
Full papers/articles (Journal)
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer, F; Schlintl, V; Hecht, S; Hackl, H; Melchardt, T; Rinnerthaler, G; Greil, R; Weiss, L;
Clin Colorectal Cancer. 2019; 18(2):159-166.e3
Full papers/articles (Journal)
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.
Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wöhrer, S; Wölfler, A; Gisslinger, H;
Wien Klin Wochenschr. 2019; 131(1-2):47
Corrections
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig, H; Poenisch, W; Knop, S; Egle, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Melchardt, T; Greil, R; Zojer, N
BRIT J CANCER. 2019; 121(9): 751-757.
Full papers/articles (Journal)
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.
Schlick, K; Magnes, T; Huemer, F; Ratzinger, L; Weiss, L; Pichler, M; Melchardt, T; Greil, R; Egle, A;
J Clin Med. 2019; 8(11):
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Unmaintained remission after discontinuation of kinase inhibitor treatment in chronic lymphocytic leukemia: an observational cohort
Egle, A; Jager, U; Skrabs, C; Durig, J; Nosslinger, T; Wanner, D; Steurer, M; Ringshausen, I; Melchardt, T; Greil, R; Ysebaert, L
ONCOL RES TREAT. 2019; 42: 18-18.
Abstracts (Journal)
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2019; 79(4):
Abstracts (Journal)
2018
Journal Articles
Austrian recommendations for the management of polycythemia vera.
Burgstaller, S; Buxhofer-Ausch, V; Sliwa, T; Beham-Schmid, C; Gastl, G; Geissler, K; Melchardt, T; Krauth, M; Krippl, P; Petzer, A; Rumpold, H; Wölfler, A; Gisslinger, H;
Wien Klin Wochenschr. 2018; 130(17-18):535-542
Full papers/articles (Journal)
Remission maintenance treatment options in chronic lymphocytic leukemia.
Egle, A; Pleyer, L; Melchardt, T; Hartmann, TN; Greil, R;
Cancer Treat Rev. 2018; 70:56-66
Reviews
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(10): 1825-1839.
Full papers/articles (Journal)
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(9):1745
Corrections
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
Krauth, MT; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Keil, F; Krippl, P; Melchardt, T; Petzer, A; Rumpold, H; Sliwa, T; Wöhrer, S; Wölfler, A; Gisslinger, H;
Wien Klin Wochenschr. 2018; 130(17-18): 495-504.
Full papers/articles (Journal)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2018; 18(3):-479
Full papers/articles (Journal)
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A;
Eur J Cancer. 2018; 93:69-78
Full papers/articles (Journal)
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R;
BMC Cancer. 2018; 18(1): 1074
Full papers/articles (Journal)
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick, K; Magnes, T; Ratzinger, L; Jaud, B; Weiss, L; Melchardt, T; Greil, R; Egle, A;
PLoS One. 2018; 13(11): e0206688
Full papers/articles (Journal)
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
Westphal, T; Rinnerthaler, G; Gampenrieder, SP; Niebauer, J; Thaler, J; Pfob, M; Fuchs, D; Riedmann, M; Mayr, B; Reich, B; Melchardt, T; Mlineritsch, B; Pleyer, L; Greil, R;
Cancer Med. 2018; 7(12):596-5972
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Forjan, E; Willenbacher, E; Wolf, D; Kralovics, R; Gisslinger, B; Stampfl-Mattersberger, M; Egle, A; Melchardt, T; Burgstaller, S; Schalling, M; Krauth, MT; Greil, R; Kadlecova, P; Zoerer, M; Empson, V; Grohmann-Izay, B; Klade, C
BLOOD. 2018; 132:
Abstracts (Journal)
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Geisberger, R; Asslaber, D; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 307-307.
Abstracts (Journal)
Spatial heterogeneity in diffuse large B-cell lymphoma
Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 243-244.
Abstracts (Journal)
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Fridrik, M; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, C; Bartsch, R; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2018; 78(4):
Abstracts (Journal)
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2018; 78(13):
Abstracts (Journal)
2017
Journal Articles
Multiple myeloma of the mandibular condyle: a rare presentation.
Bottini, GB; Steiner, C; Melchardt, T; Gaggl, A;
Br J Oral Maxillofac Surg. 2017; 55(10):1046-1047
Letters
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Case Reports
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka, L; Drucker, C; Skrabs, C; Thomas, W; Melchardt, T; Struve, S; Bergmann, M; Staber, PB; Porpaczy, E; Einberger, C; Heinz, M; Hauswirth, A; Raderer, M; Pabinger, I; Thalhammer, R; Egle, A; Wendtner, CM; Follows, G; Hoermann, G; Quehenberger, P; Jilma, B; Jaeger, U;
Leukemia. 2017; 31(5): 1117-1122.
Full papers/articles (Journal)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter, B; Willenbacher, E; Willenbacher, W; Egle, A; Neumeister, P; Voskova, D; Mayerhoefer, ME; Simonitsch-Klupp, I; Melchardt, T; Greil, R; Raderer, M;
Blood. 2017; 129(3):-385
Full papers/articles (Journal)
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T; Egle, A; Greil, R; Melchardt, T;
MEMO-MAG EUR MED ONC. 2017; 10(4): 220-223.
Reviews
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes, T; Melchardt, T; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Gampenrieder, S; Moser, G; Gaggl, A; Greil, R; Egle, A;
PLoS One. 2017; 12(7):e0180995
Full papers/articles (Journal)
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Hackl, H; Greil, R; Barth, J; Rummel, M;
Ann Hematol. 2017; 96(7): 1155-1162.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVERA STUDY
Buxhofer-Ausch, V; Grohmann-Izay, B; Thaler, J; Schloegl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Greil, R; Zoerer, M; Kadlecova, P; Klade, C; Gisslinger, H
HAEMATOLOGICA. 2017; 102: 284-284.
Abstracts (Journal)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2017; 77:
Abstracts (Journal)
2016
Journal Articles
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Fridrik, M; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A;
Lancet Haematol. 2016; 3(7):e317-e329
Full papers/articles (Journal)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T; Melchardt, T; Weiss, L; Hufnagl, C; Greil, R; Egle, A;
J Clin Oncol. 2016; 34(20):2433-2434
Letters
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T; Hufnagl, C; Weinstock, DM; Kopp, N; Neureiter, D; Tränkenschuh, W; Hackl, H; Weiss, L; Rinnerthaler, G; Hartmann, TN; Greil, R; Weigert, O; Egle, A;
Oncotarget. 2016; 7(32):51494-51502
Full papers/articles (Journal)
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka, KT; Melchardt, T; Posch, F; Schlick, K; Deutsch, A; Beham-Schmid, C; Weiss, L; Gary, T; Neureiter, D; Klieser, E; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Br J Cancer. 2016; 115(10):1264-1272
Full papers/articles (Journal)
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.
Troppan, KT; Melchardt, T; Wenzl, K; Schlick, K; Deutsch, A; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Tränkenschuh, W; Greil, R; Neumeister, P; Egle, A; Pichler, M;
J Clin Pathol. 2016; 69(4):326-330
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Mlineritsch, B; Greil, R
ANN ONCOL. 2016; 27:
Abstracts (Journal)
2015
Journal Articles
Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases.
Berghoff, AS; Ilhan-Mutlu, A; Dinhof, C; Magerle, M; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Pichler, J; Hutterer, M; Melchardt, T; Bartsch, R; Zielinski, CC; Birner, P; Preusser, M;
Neuropathol Appl Neurobiol. 2015; 41(2):e41-e55
Full papers/articles (Journal)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger, H; Zagrijtschuk, O; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Them, NC; Kadlecova, P; Klade, C; Greil, R;
Blood. 2015; 126(15):1762-1769
Full papers/articles (Journal)
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.
Huemer, F; Melchardt, T; Tränkenschuh, W; Neureiter, D; Moser, G; Magnes, T; Weiss, L; Schlattau, A; Hufnagl, C; Ricken, G; Höftberger, R; Greil, R; Egle, A;
BMC Cancer. 2015; 15:996
Case Reports
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt, T; Hufnagl, C; Magnes, T; Weiss, L; Hutarew, G; Neureiter, D; Schlattau, A; Moser, G; Gaggl, A; Tränkenschuh, W; Greil, R; Egle, A;
BMC Cancer. 2015; 15:725
Full papers/articles (Journal)
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Hopfinger, G; Magnes, T; Deutsch, A; Neumeister, P; Hackl, H; Greil, R; Pichler, M; Egle, A;
Br J Haematol. 2015; 168(2):239-245
Full papers/articles (Journal)
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A;
J Natl Compr Canc Netw. 2015; 13(12):1501-1508
Full papers/articles (Journal)
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Auberger, J; Steinkirchner, S; Pleyer, L; Greil, R; Egle, A;
Leuk Lymphoma. 2015; 56(2):353-360
Full papers/articles (Journal)
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them, NC; Bagienski, K; Berg, T; Gisslinger, B; Schalling, M; Chen, D; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zagrijtschuk, O; Klade, C; Greil, R; Gisslinger, H; Kralovics, R;
Am J Hematol. 2015; 90(4):288-294
Full papers/articles (Journal)
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Eur J Haematol. 2015; 95(6):538-544
Full papers/articles (Journal)
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.
Wasle, I; Gamerith, G; Kocher, F; Mondello, P; Jaeger, T; Walder, A; Auberger, J; Melchardt, T; Linkesch, W; Fiegl, M; Mian, M;
Ann Hematol. 2015; 94(4): 593-601.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Buxhofer-Ausch, V; Gisslinger, H; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Them, NCC; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Journal)
MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial
Egle, A; Doubek, M; Stehlikova, O; Pleyer, L; Altenhofer, P; Melchardt, T; Smolej, L; Mihaylov, GG; Mikuskova, E; Mayer, J; Greil, R
LEUKEMIA LYMPHOMA. 2015; 56: 123-124.
Abstracts (Journal)
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Schalling, M; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Krauth, MT; Them, NCC; Kralovics, R; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Journal)
Combination of age, ABC-type and intratumoral
T-regulator cells are a negative prognostic factors for
primary extranodal diffuse large B-cell lymphoma
Tränkenschuh, W; Kemmerling, R; Alinger, B; Melchardt, T; Egle, A; Kiesslich, T; Neureiter, D
PATHOLOGE . 2015; 36: 110-110.
Abstracts (Journal)
2014
Journal Articles
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.
Berghoff, AS; Ilhan-Mutlu, A; Wöhrer, A; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Melchardt, T; Dome, B; Heinzl, H; Birner, P; Preusser, M;
Strahlenther Onkol. 2014; 190(7):676-685
Full papers/articles (Journal)
αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.
Berghoff, AS; Kovanda, AK; Melchardt, T; Bartsch, R; Hainfellner, JA; Sipos, B; Schittenhelm, J; Zielinski, CC; Widhalm, G; Dieckmann, K; Weller, M; Goodman, SL; Birner, P; Preusser, M;
Clin Exp Metastasis. 2014; 31(7):841-851
Full papers/articles (Journal)
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Melchardt, T; Egle, A; Rebhandl, S; Catakovic, K; Hartmann, TN; Greil, R; Geisberger, R;
Haematologica. 2014; 99(5):67-69
Letters
Kasabach-Merritt phenomenon in hepatic angiosarcoma.
Habringer, S; Boekstegers, A; Weiss, L; Hopfinger, G; Meissnitzer, T; Melchardt, T; Egle, A; Greil, R;
Br J Haematol. 2014; 167(5):716-718
Letters
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R;
Ann Hematol. 2014; 93(3):459-462
Full papers/articles (Journal)
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A;
BMC COMPLEM ALTERN M. 2014; 14: 115
Case Reports
Pleural decortication of a marginal zone lymphoma.
Melchardt, T; Weiss, L; Namberger, K; Pretsch, I; Hutter, J; Rettenbacher, L; Neureiter, D; Troch, M; Greil, R; Egle, A;
Ann Hematol. 2014; 93(7):1253-1254
Letters
R-CHOP versus R-COMP: Are They Really Equally Effective?
Mian, M; Wasle, I; Gamerith, G; Mondello, P; Melchardt, T; Jäger, T; Linkesch, W; Fiegl, M;
Clin Oncol (R Coll Radiol). 2014; 26(10): 648-652.
Full papers/articles (Journal)
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M;
Br J Cancer. 2014; 111(1):55-60
Full papers/articles (Journal)
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Weiss, L; Melchardt, T; Habringer, S; Boekstegers, A; Hufnagl, C; Neureiter, D; Hopfinger, G; Greil, R; Egle, A;
Ann Oncol. 2014; 25(1):171-176
Full papers/articles (Journal)
2013
Journal Articles
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].
Melchardt, T; Weiss, L; Egle, A;
Dtsch Med Wochenschr. 2013; 138(41): 2093-2095.
Case Reports
What’s new in Hodgkin’s lymphoma: ASH 2012 and more
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 193-196.
Reviews
Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Leuk Lymphoma. 2013; 54(8):1602-1613
Reviews
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Auberger, J; Hopfinger, G; Greil, R; Egle, A;
Oncol Lett. 2013; 6(6):1756-1758
Full papers/articles (Journal)
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger, K; Weiss, L; Krause, B; Melchardt, T; Greil, R;
Eur J Haematol. 2013; 90(4):349-350
Letters
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Sliwa, T; Egle, A; Linkesch, W; Voskova, D; Angermann, H; Greil, R;
J HEMATOL ONCOL. 2013; 6: 32
Full papers/articles (Journal)
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor, N; Melchardt, T; Grundbichler, M; Strasser, M; Egle, A; Greil, R;
Ann Hematol. 2013; 92(7):1001-1002
Letters
ASH 2012 update chronic lymphocytic leukemia—the best is yet to come
Weiss, L; Melchardt, T; Greil, R; Hopfinger, G;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 177-180.
Reviews
Conference papers, proceedings, abstracts
Influence of Body Mass Index on survival in indolent and Mantle-cell Lymphomas: Analysis of the StiL1 trial
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Greil, R; Barth, J; Rummel, M
ONKOLOGIE. 2013; 36: 31-32.
Abstracts (Journal)
Book chapters
Diagnostik und Therapie von diffus großzelligen Lymphomen (DLBCL)
Egle, A; Melchardt, T; Weiss, L;
In: Hopfinger, G; Greil, R (Hrsg.) editors(s). Aktuelle Diagnostik und Therapieoptionen bei aggressiven Lymphomen.. Bremen, London, Boston: UniMed Verlag; p. 26-35. (ISBN: 978-3-8374-1407-3)
Newspaper/magazine articles
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results
Egle, A; Steurer, M; Gassner, FJ; Geisberger, R; Melchardt, T; Pleyer, L; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R;
Blood (ASH Annual Meeting Abstracts). 2013. #4164:
2012
Journal Articles
Treating T-cell lymphoma: is there a light at the end of the tunnel?
Hopfinger, G; Merkel, O; Melchardt, T; Greil, R;
Magazine of European Medical Oncology. 2012; 5 (3): 174-177.
Full papers/articles (Journal)
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel, O; Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Kocher, T; Denk, U; Hofbauer, JP; Egle, A; Scheideler, M; Schlederer, M; Steurer, M; Kenner, L; Greil, R;
Leukemia. 2012; 26(12):2508-2516
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Gisslinger, H; Kralovics, R; Gisslinger, B; Lechner, D; Buxhofer-Ausch, V; Strecker, K; Gastl, G; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Schloegl, E; Tarmann, FJ; Zoerer, M; Klade, C; Zahriychuk, O; Thaler, J
BLOOD. 2012; 120(21):
Abstracts (Journal)
Feasibility of anthracycline based treatment in unselected elderly DLBCL patients
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Hopfinger, G; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 86-87.
Abstracts (Journal)
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Greil, R; Egle, A
BLOOD. 2012; 120(21):
Abstracts (Journal)
Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 149-149.
Abstracts (Journal)
2011
Journal Articles
ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.
Melchardt, T; Hofbauer, SW; Greil, R; Hopfinger, G
memo - Magazine of European Medical Oncology. 2011; 4: 120-123.
Reviews
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss, L; Melchardt, T; Egle, A; Grabmer, C; Greil, R; Tinhofer, I;
Cancer. 2011; 117(10):2163-2169
Full papers/articles (Journal)
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss, L; Melchardt, T; Neureiter, D; Kemmerling, R; Moshir, S; Pleyer, L; Greil, R; Egle, A;
J CLIN ONCOL. 2011; 29(24): e696-e698.
Case Reports
Conference papers, proceedings, abstracts
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
Egle, A; Steurer, M; Gassner, F; Geisberger, R; Melchardt, T; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R
BLOOD. 2011; 118(21): 135-136.
Abstracts (Journal)
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Gisslinger, H; Kralovics, R; Schoder, R; Gisslinger, B; Buxhofer-Ausch, V; Strecker, K; Wolf, D; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Tarmann, FJ; Wachter, C; Zahriycick, O; Thaler, J
BLOOD. 2011; 118(21): 762-762.
Abstracts (Journal)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Egle, A; Sliwa, T; Linkesch, W; Fridrik, MA; Greil, R
BLOOD. 2011; 118(21): 747-747.
Abstracts (Journal)
Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia
Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Denk, U; Pinon-Hofbauer, J; Egle, A; Kocher, T; Steurer, M; Greil, R; Merkel, O
ONKOLOGIE. 2011; 34: 141-141.
Abstracts (Journal)
2010
Journal Articles
An uncommon cause of anaemia: Sheehan"s syndrome.
Melchardt, T; Namberger, K; Weiss, L; Egle, A; Faber, V; Greil, R;
WIEN KLIN WOCHENSCHR. 2010; 122(23-24): 717-719.
Case Reports
Conference papers, proceedings, abstracts
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
Egle, A; Weiss, L; Melchardt, T; Gunsilius, E; Petzer, AL; Fridrik, M; Lang, A; Krieger, O; Thaler, J; Greil, R
BLOOD. 2010; 116(21): 593-594.
Abstracts (Journal)
Book chapters
Rare Clonal Myeloid Diseases
Melchardt, T; Weiss, L; Pleyer, L; Neureiter, D; Faber, V; Greil, R;
In: Greil, R; Pleyer, L; Faber, V; Neureiter, D (Eds.)
editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Springer; (ISBN: 978-3-211-79891-1)
2009
Journal Articles
[Implementation of evidence based medicine in primary care].
Rinnerberger, A; Grafinger, M; Melchardt, T; Sönnichsen, A;
Wien Med Wochenschr. 2009; 159(7-8): 207-210.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A; Melchardt, T; Pleyer, L; Tinhofer, I; Lang, A; Keil, F; Thaler, J; Gunsilius, E; Fridrik, M; Greil, R
HAEMATOL-HEMATOL J. 2009; 94: 140-140.
Abstracts (Journal)
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
Egle, A; Steurer, M; Melchardt, T; Stoll, M; Greil, R
BLOOD. 2009; 114(22): 1341-1342.
Abstracts (Journal)
The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia
Weiss, L; Melchardt, T; Grabmer, C; Egle, A; Tinhofer, I; Greil, R
BLOOD. 2009; 114(22): 510-510.
Abstracts (Journal)